University of Virginia, Department of Psychiatry and Neurobehavioral Sciences, Charlottesville, 22908, USA.
Expert Opin Drug Saf. 2009 Nov;8(6):655-68. doi: 10.1517/14740330903279956.
The safety profile of newer stimulant products is of interest. Because most studies focus on school-age children, there is also an increased interest in the treatment of other populations. Concern continues for the risk of substance abuse in the use of stimulants.
The purpose of this paper is to review published data on the safety and tolerability of the newer forms of stimulants, treatment in special populations, and the risks of substance abuse and dependence in the treatment of attention deficit hyperactivity disorder.
Literature obtained through Medline and Pubmed from 1995 were reviewed as well as key articles referenced in the literature.
The use of the newer stimulant agents shows a safety profile of frequent, but usually mild side effects. They are generally safe in special populations. The risk of developing long-term substance abuse with attention deficit hyperactivity disorder, without co-morbidities, is small and may decrease with proper treatment. More research is needed.
新型兴奋剂产品的安全性备受关注。由于大多数研究都集中在学龄儿童，因此也越来越关注其他人群的治疗。人们仍然担心在使用兴奋剂时存在滥用药物的风险。
本文旨在回顾已发表的关于新型兴奋剂的安全性和耐受性、特殊人群治疗以及治疗注意缺陷多动障碍时药物滥用和依赖风险的相关数据。
通过 Medline 和 Pubmed 检索了 1995 年以来的文献，并查阅了文献中的关键文章。
新型兴奋剂药物的使用具有频繁但通常是轻微的副作用的安全性特征。它们在特殊人群中通常是安全的。没有合并症的情况下，患有注意缺陷多动障碍长期药物滥用的风险较小，且随着适当的治疗可能会降低。还需要更多的研究。
